Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
about
C/EBPα Dysregulation in AML and ALLPrognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study GroupCEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese populationMyeloid neoplasias: what molecular analyses are telling usLong-term follow-up of cytogenetically normal CEBPA-mutated AMLDouble CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD.The multifaceted functions of C/EBPα in normal and malignant haematopoiesis.Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expressionNovel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression arrayAcute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemiaThe potential of a single enhancerRecognizing familial myeloid leukemia in adults.Whole exome sequencing reveals a C-terminal germline variant in CEBPA-associated acute myeloid leukemia: 45-year follow up of a large family.Clinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.Nanochannel Electroporation as a Platform for Living Cell Interrogation in Acute Myeloid Leukemia.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.The use of molecular genetics to refine prognosis in acute myeloid leukemia.Transcription factor mutations in myelodysplastic/myeloproliferative neoplasmsBiological and clinical consequences of NPM1 mutations in AML.The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia.BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.Reply to 'Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favorable prognosis'.Concordant acute myeloblastic leukemia in monozygotic twins with germline and shared somatic mutations in the gene for CCAAT-enhancer-binding protein α with 13 years difference at onset.CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.Molecular and cellular effects of oncogene cooperation in a genetically accurate AML mouse model.Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.Full-length mutation search of the TP53 gene in acute myeloid leukemia has increased significance as a prognostic factor.The added values of multiplex reverse transcriptase-PCR followed by mutation screening in the initial evaluation of acute leukemia.Prognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia.
P2860
Q22065117-DD1ACF81-92AB-43BC-A571-41BA02B31AE9Q27853039-3594E47A-FD0D-48BF-BFA6-6916AECF2361Q31111079-5E30D95E-4674-4136-A4C8-3440AC8AB7DEQ33354547-BAE8BA9E-673D-4406-B218-E5705E2D1475Q34233639-3FC68542-4890-42F1-A325-AA1B281C6962Q34502042-135B589A-8001-4075-849C-F5278B921EF8Q34502869-EEBEA8D8-A375-4CD9-B785-BEE7C7997A3AQ34635511-3C9D570B-846D-488C-971C-A89AD8CDC792Q34649120-95CA499A-8870-4186-AA96-09E57F543A33Q35788613-B4733303-8536-49B7-98E3-FD123740DEAAQ36457184-DFE7C457-3554-4BAF-9884-7691DC041574Q36789391-AE6231E6-DB3C-4356-884F-C0D2D996EFA6Q36849666-7BB29F27-A5B7-4169-A576-8BB1D6E3E89CQ36925156-1E3E4C41-C219-40B0-83B6-D082707CC0E4Q37015672-2828C11B-A5E1-4591-B9AE-8A73A42447B6Q37073883-62AB17D2-4736-4C69-AFEE-132A5446096EQ37216459-6F0F10F1-D153-4914-BA6C-793E106DDB90Q37331218-B9A934FC-F4C2-4E8B-9319-59633D3EAE6CQ37422939-484D4270-342A-43FD-80B4-BB1DF7F56CE3Q37624593-E692C631-2D80-4769-9CCB-0BB13A9C37C8Q37712353-A411C6CF-7D95-4629-A067-2C8B6F8BDE1AQ38198569-EF1DC1C6-E941-4EA3-9F15-40692AF62B7CQ38344558-C6D3537D-2A1A-4557-9D75-7CF562241889Q39098284-2E3460AA-A874-4506-89FC-F26B9FD75035Q40202671-C46C0726-444D-4A5C-9EC5-471821776055Q41197435-239B1B78-C3FE-4CF2-8C60-93DF0BEAB4F0Q41885481-B8E310FB-2C9A-4DE0-A952-939C76A28ED7Q42113668-694E409A-8BD2-4705-9BD9-CE2DAAE3E89EQ42543838-6D8328F8-F1F3-4C3D-827C-DC77F93D0308Q43111395-B805C17C-757A-4764-BB68-10156E8A909EQ43466307-CBE6C496-A5C9-4C16-8A51-DB2AE9954FF0Q43579359-D10AE6E0-21C2-41C9-8A9A-1CEFB38E5003Q44959828-C631F52D-05FB-44C1-9D73-8AF767FB1FA1Q45176487-BFDA1794-4CC9-4C4C-9A6E-146F8F0DB875Q45876973-53F33AD4-6B81-49C1-9103-AF9E83D5E298Q47660404-28E9D7D0-C261-4901-B975-3FEAE5D569A4Q48242145-C9D45941-552D-43EE-B108-4829213A8FCCQ51694552-83171257-F43E-40AD-92E9-BF4934F9496AQ54307737-F234DF09-B1DD-4BBE-8BCE-E3BFCBC9760E
P2860
Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Heterogeneity within AML with ...... ated with favourable prognosis
@en
Heterogeneity within AML with ...... ted with favourable prognosis.
@nl
type
label
Heterogeneity within AML with ...... ated with favourable prognosis
@en
Heterogeneity within AML with ...... ted with favourable prognosis.
@nl
prefLabel
Heterogeneity within AML with ...... ated with favourable prognosis
@en
Heterogeneity within AML with ...... ted with favourable prognosis.
@nl
P2093
P2860
P356
P1476
Heterogeneity within AML with ...... ated with favourable prognosis
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604977
P407
P577
2009-03-10T00:00:00Z
P5875
P6179
1013804161